L575-0657 Screening compound: 4-[1-methyl-3-(morpholine-4-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-N-[3-(3-methylpiperidin-1-yl)propyl]-4-oxobutanamide

L575-0657 Screening compound: 4-[1-methyl-3-(morpholine-4-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-N-[3-(3-methylpiperidin-1-yl)propyl]-4-oxobutanamide
L575-0657 Screening compound: 4-[1-methyl-3-(morpholine-4-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-N-[3-(3-methylpiperidin-1-yl)propyl]-4-oxobutanamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L575-0657
4-[1-methyl-3-(morpholine-4-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-N-[3-(3-methylpiperidin-1-yl)propyl]-4-oxobutanamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L575-0657

Molecular Formula

C25H40N6O4 (C25 H40 N6 O4)

Compound Name

4-[1-methyl-3-(morpholine-4-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-N-[3-(3-methylpiperidin-1-yl)propyl]-4-oxobutanamide

IUPAC name

4-[1-methyl-3-(morpholine-4-carbonyl)-1H4H5H6H7H-pyrazolo[43-c]pyridin-5-yl]-N-[3-(3-methylpiperidin-1-yl)propyl]-4-oxobutanamide

SMILES

CC1CN(CCCNC(CCC(N(CC2)Cc3c2n(C)nc3C(N2CCOCC2)=O)=O)=O)CCC1

InChI

InChI=1S/C25H40N6O4/c1-19-5-3-10-29(17-19)11-4-9-26-22(32)6-7-23(33)31-12-8-21-20(18-31)24(27-28(21)2)25(34)30-13-15-35-16-14-30/h19H,3-18H2,1-2H3,(H,26,32)/t19-/m0/s1

InChI Key

GCCAGZHQWQJDTA-IBGZPJMESA-N

MDL Number (MFCD)

MFCD27463579

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

488.63

Hydrogen Bond Acceptors Count

9.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

11.00

Number of Nitrogen and Oxygen Atoms

10

Partition Coefficient, logP

-1.065

Distribution Coefficient, logD

-3.695

Water Solubility, LogSw

-0.59

Polar Surface Area

83.825

Acid Dissociation Constant (pKa)

15.45

Base Dissociation Constant (pKb)

10.03

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

76.00

L575-0657 in Drug Discovery

Included in Screening Libraries

Anticancer Library (62698 compounds)

Cysteine Proteases Inhibitors Library (7839 compounds)

Hsp90-Targeted Library (11355 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Nervous system
  • Cardiovascular
  • Skin
  • Metabolic
  • Endocrine
  • Immune system
  • Cancer
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Immune system
Targets:
  • Proteases

References: we are preparing a list of scientific research reports with L575-0657 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L575-0657?
Check Price and Availability of L575-0657, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L575-0657 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L575-0657
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L575-0657
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L575-0657 available by request